<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611765</url>
  </required_header>
  <id_info>
    <org_study_id>H-22816</org_study_id>
    <nct_id>NCT02611765</nct_id>
  </id_info>
  <brief_title>Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study</brief_title>
  <official_title>Syphilis Response to Higher Penicillin Dosage in HIV Co-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Syphilis remains a significant health problem worldwide, with an estimated 10.6 million new
      cases per year. Due to shared transmission route and risk factors, co-infection with syphilis
      and Human Immunodeficiency Virus (HIV) is not uncommon. Several studies have evaluated the
      response to syphilis treatment in HIV-infected patients. They support the claim that patients
      with HIV have a slower decrease in syphilis antibody titers, and that they may progress to
      neurosyphilis in earlier stages.

      The Center for Disease Control and Prevention's Sexually Transmitted Disease Treatment
      Guidelines has advocated treating HIV-infected patients who have primary, secondary syphilis
      or early latent syphilis with the same doses of penicillin as for HIV-uninfected patients
      (single dose of 2.4 million units of benzathine penicillin G). The investigators designed a
      randomized controlled trial in order to compare the efficacy of three- versus single-dosed
      regimens of intramuscular benzathine penicillin G (BPG) for the treatment of early syphilis
      in HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conducted a prospective, randomized, open label study at three clinical
      sites including Thomas Street Health Center and North West Clinic (Harris Health System), and
      the Michael E. DeBakey Veterans Affairs Medical Center in Houston, Texas. After obtaining
      written informed consent, the investigators randomly assigned patients to either a single
      intramuscular injection of 2.4 million units of BPG (standard therapy) or three doses
      (enhanced therapy) of intramuscular BPG administered weekly (a total of 7.2 million units).

      Patients were eligible for inclusion in the study if they were 18 years of age or older and
      had a diagnosis of HIV. The diagnosis of syphilis was made based on a positive Rapid Plasma
      Reagin (RPR) and treponema pallidum particle agglutination tests. Patients with primary,
      secondary and early latent syphilis were included.

      Exclusion criteria were history of penicillin allergy, diagnosis of late latent syphilis,
      neurosyphilis, and antibiotic use with significant activity against Treponema pallidum within
      the preceding two weeks.

      Follow-up period was 12 months. Serum samples were obtained at initial visit and follow-up
      visits every 3 months for serological testing for syphilis. Treatment success was defined as
      a decrease in RPR titer of &gt;= 2 dilutions (4-fold) from the initial RPR titer during the
      follow-up period.

      Both intention-to-treat and per-protocol analyses were performed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of &gt;= 2 Dilutions (4-fold)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who achieve treatment success. Loss to follow-up was assumed to be a failure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>Enhanced therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzathine penicillin G intramuscular 7.2 million units</intervention_name>
    <description>Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).</description>
    <arm_group_label>Enhanced therapy</arm_group_label>
    <other_name>Enhanced therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzathine penicillin G intramuscular 2.4 million units</intervention_name>
    <description>A single dose of intramuscular 2.4 million units of benzathine penicillin G</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with HIV by ELISA and confirmed by Western blot

          -  Positive Rapid Plasma Reagin and treponema pallidum particle agglutination tests

        Exclusion Criteria:

          -  History of penicillin allergy

          -  Diagnosis of late latent syphilis

          -  Diagnosis of neurosyphilis

          -  Antibiotic use with significant activity against Treponema pallidum within the
             preceding two weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose A Serpa-Alvarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor (Medicine: Infectious Disease)</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2016</results_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Jose Serpa-Alvarez</investigator_full_name>
    <investigator_title>Co-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enhanced Therapy</title>
          <description>Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
Enhanced therapy: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).</description>
        </group>
        <group group_id="P2">
          <title>Standard Therapy</title>
          <description>A single intramuscular injection of 2.4 million units of benzathine penicillin G
Standard therapy: A single dose of intramuscular 2.4 million units of benzathine penicillin G</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enhanced Therapy</title>
          <description>Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
Enhanced therapy: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).</description>
        </group>
        <group group_id="B2">
          <title>Standard Therapy</title>
          <description>A single intramuscular injection of 2.4 million units of benzathine penicillin G
Standard therapy: A single dose of intramuscular 2.4 million units of benzathine penicillin G</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="11"/>
                    <measurement group_id="B2" value="35" spread="10"/>
                    <measurement group_id="B3" value="35" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Whites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African Americans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of &gt;= 2 Dilutions (4-fold)</title>
        <description>Number of participants who achieve treatment success. Loss to follow-up was assumed to be a failure.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Therapy</title>
            <description>Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
Enhanced therapy: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>A single intramuscular injection of 2.4 million units of benzathine penicillin G
Standard therapy: A single dose of intramuscular 2.4 million units of benzathine penicillin G</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of &gt;= 2 Dilutions (4-fold)</title>
          <description>Number of participants who achieve treatment success. Loss to follow-up was assumed to be a failure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enhanced Therapy</title>
          <description>Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
Enhanced therapy: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).</description>
        </group>
        <group group_id="E2">
          <title>Standard Therapy</title>
          <description>A single intramuscular injection of 2.4 million units of benzathine penicillin G
Standard therapy: A single dose of intramuscular 2.4 million units of benzathine penicillin G</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jose Serpa-Alvarez</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713 798-7910</phone>
      <email>jaserpaa@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

